When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. FDA-approved drug for ulcerative colitis also effective for ...

   www.aol.com/fda-approved-drug-ulcerative-colitis...

   “Despite continued advances, people living with ulcerative colitis and Crohn’s disease are still seeking treatments that can address difficult-to-manage symptoms, such as bowel urgency, and ...

3. Targeted therapy may help treat moderate to severe ulcerative ...

   www.aol.com/targeted-therapy-may-help-treat...

   “There has been a great deal of progress in developing new, more effective and safe agents to treat inflammatory bowel diseases (Crohn’s disease and ulcerative colitis) over the last 20 years.

4. Management of ulcerative colitis - Wikipedia

   en.wikipedia.org/wiki/Management_of_ulcerative...

   Management of ulcerative colitis involves first treating the acute symptoms of the disease, then maintaining remission. Ulcerative colitis is a form of colitis , a disease of the intestine , specifically the large intestine or colon , that includes characteristic ulcers , or open sores, in the colon.

5. Ulcerative colitis - Wikipedia

   en.wikipedia.org/wiki/Ulcerative_colitis

   As of early 2022, Roche halted clinical trials for the use of etrolizumab in the treatment of ulcerative colitis. [202] A type of leukocyte apheresis, known as granulocyte and monocyte adsorptive apheresis, still requires large-scale trials to determine whether or not it is effective. [203] Results from small trials have been tentatively ...

6. Vedolizumab - Wikipedia

   en.wikipedia.org/wiki/Vedolizumab

   Vedolizumab, sold under the brand name Entyvio, is a monoclonal antibody medication developed by Takeda Oncology for the treatment of ulcerative colitis and Crohn's disease. [5] It binds to integrin α 4 β 7 ( LPAM-1 , lymphocyte Peyer's patch adhesion molecule 1, a dimer of Integrin alpha-4 and Integrin beta-7 ), [ 5 ] [ 6 ] blocking the α 4 ...

7. Monoclonal antibody therapy - Wikipedia

   en.wikipedia.org/wiki/Monoclonal_antibody_therapy

   [6] [7] These advances allowed for the specific targeting of tumors both in vitro and in vivo. Initial research on malignant neoplasms found mAb therapy of limited and generally short-lived success with blood malignancies. [8] [9] Treatment also had to be tailored to each individual patient, which was impracticable in routine clinical settings.